Catalyst Biosciences’ Factor IX Recommended for Orphan Drug Designation in Europe
May 31, 2017 12:22 pm UTC| Business
SOUTH SAN FRANCISCO, Calif., May 31, 2017 -- Catalyst Biosciences, Inc. (Nasdaq:CBIO), a clinical-stage biopharmaceutical company focused on developing novel medicines to address hematology indications, today announced...
Catalyst Biosciences’ Factor IX Recommended for Orphan Drug Designation in Europe
May 31, 2017 12:22 pm UTC| Business
SOUTH SAN FRANCISCO, Calif., May 31, 2017 -- Catalyst Biosciences, Inc. (Nasdaq:CBIO), a clinical-stage biopharmaceutical company focused on developing novel medicines to address hematology indications, today announced...
Catalyst Biosciences’ Factor IX Recommended for Orphan Drug Designation in Europe
May 31, 2017 12:22 pm UTC| Business
SOUTH SAN FRANCISCO, Calif., May 31, 2017 -- Catalyst Biosciences, Inc. (Nasdaq:CBIO), a clinical-stage biopharmaceutical company focused on developing novel medicines to address hematology indications, today announced...
Catalyst Biosciences’ Factor IX Recommended for Orphan Drug Designation in Europe
May 31, 2017 12:22 pm UTC| Business
SOUTH SAN FRANCISCO, Calif., May 31, 2017 -- Catalyst Biosciences, Inc. (Nasdaq:CBIO), a clinical-stage biopharmaceutical company focused on developing novel medicines to address hematology indications, today announced...
Catalyst Biosciences’ Factor IX Recommended for Orphan Drug Designation in Europe
May 31, 2017 12:22 pm UTC| Business
SOUTH SAN FRANCISCO, Calif., May 31, 2017 -- Catalyst Biosciences, Inc. (Nasdaq:CBIO), a clinical-stage biopharmaceutical company focused on developing novel medicines to address hematology indications, today announced...
Catalyst Biosciences’ Factor IX Recommended for Orphan Drug Designation in Europe
May 31, 2017 12:22 pm UTC| Business
SOUTH SAN FRANCISCO, Calif., May 31, 2017 -- Catalyst Biosciences, Inc. (Nasdaq:CBIO), a clinical-stage biopharmaceutical company focused on developing novel medicines to address hematology indications, today announced...
Catalyst Biosciences’ Factor IX Recommended for Orphan Drug Designation in Europe
May 31, 2017 12:22 pm UTC| Business
SOUTH SAN FRANCISCO, Calif., May 31, 2017 -- Catalyst Biosciences, Inc. (Nasdaq:CBIO), a clinical-stage biopharmaceutical company focused on developing novel medicines to address hematology indications, today announced...
US–India Trade Turbocharge: Stocks Poised to Ride the Export Wave